---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-027930"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:05:19.986061+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q3 net revenue $55.8M (incl. $30M milestone); lowers FY22 product revenue guidance to $100-105M

## Summary
- Net loss narrowed to $9.0M ($0.06/sh) from $50.3M loss ($0.39/sh) in Q3 2021.
- LUPKYNIS net product revenue $25.5M; 2022 product revenue guidance cut to $100-105M from unstated prior range.
- Patients on therapy grew to ~1,354 (up from 1,274 at Q2 2022); PSFs added 374 vs 412 Y/Y.
- EC granted marketing authorization for LUPKYNIS in Europe; $30M milestone from Otsuka recognized and received.
- Cash at $376.6M (Sep 30) and ~$400M (Oct 31); IPR decision on LUPKYNIS patent expected by July 26, 2023.

## SEC filing metadata
- accession: 0001628280-22-027930
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828022027930/0001628280-22-027930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828022027930/auph-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-027930
- JSON: https://secwatch.observer/filing/0001628280-22-027930.json
- Plain text: https://secwatch.observer/filing/0001628280-22-027930.txt

## Key facts
- Earnings Releases
  Aurinia Pharmaceuticals Inc. updated its 2022 guidance (lowered).
  - Period: 2022
  - Guidance: lowered
  - Result: guidance update
  source text: we are adjusting our net revenue guidance to $100-105 million from sales of LUPKYNIS for 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000162828022027930/0001628280-22-027930-index.htm
- Earnings Releases
  Aurinia Pharmaceuticals Inc. reported the three months ended September 30, 2022 results: revenue $55.8 million.
  - Period: the three months ended September 30, 2022
  - Revenue: $55.8 million
  - Result: reported results
  source text: set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS Net revenue of $55.8 million for Q3 2022; including $30.0 million milestone from Otsuka related to European Approval of LUPKYNIS ® (voclosporin) Adjusts net product revenue guidance to $100-105 million from
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000162828022027930/0001628280-22-027930-index.htm
- Earnings Releases
  Aurinia Pharmaceuticals Inc. updated its 2023 guidance (initiated).
  - Period: 2023
  - Guidance: initiated
  - Result: guidance update
  source text: We are also providing preliminary net revenue guidance from product sales of LUPKYNIS for 2023 in the range of $120-140 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000162828022027930/0001628280-22-027930-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.